Insmed CEO William Lewis sells $1.97 million in stock

William Lewis (JO:LEWJ), Chair and CEO of Insmed Inc (NASDAQ:INSM), has sold shares worth approximately $1.97 million, according to recent filings with the Securities and Exchange Commission. The transactions, dated March 17, involved multiple sales of Insmed’s common stock at prices ranging from $75.91 to $77.83 per share. The stock, which has delivered an impressive 194% return over the past year, currently trades at $78.91. InvestingPro analysis shows strong analyst consensus with multiple growth indicators available.

The sales included 4,727 shares at an average price of $75.91, 5,907 shares at $76.87, and 8,116 shares at $77.79, among others. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following these sales, Lewis retains direct ownership of 334,186 shares of Insmed’s common stock in the $14.27 billion market cap company.

Additionally, Lewis exercised stock options to acquire 18,750 shares at prices between $10.85 and $22.76, totaling $500,855. These transactions reflect his continued involvement and interest in the company, which is headquartered in Bridgewater, New Jersey. Get comprehensive insights and detailed analysis about INSM with a InvestingPro subscription, including exclusive ProTips and Fair Value estimates.

In other recent news, several investment firms have provided updates on Insmed Incorporated, highlighting significant developments. RBC Capital Markets reaffirmed their Outperform rating with a $100 price target, focusing on Insmed’s TPIP data expected in mid-2025, which could significantly impact the company’s future prospects. UBS also maintained a positive outlook, raising their price target to $110, based on anticipated results from a Phase 2 trial of TPIP for Pulmonary Arterial Hypertension (PAH). The trial will assess the drug’s ability to reduce pulmonary vascular resistance, a critical measure of its potential success.

H.C. Wainwright continues to support Insmed with a Buy rating and a $90 price target, following their presentation of a novel gene therapy for Duchenne muscular dystrophy at the 2025 Annual MDA Conference. The therapy demonstrated promising results in animal models, suggesting potential benefits for patients with DMD. Truist Securities maintained a Buy rating and a $108 price target, expressing optimism about Insmed’s TPIP data for PAH and the commercial launch of brensocatib, expected in August 2025.

RBC Capital has also initiated coverage on Insmed, citing the potential success of brensocatib in treating bronchiectasis, which could lead to peak sales of $8.2 billion. This endorsement reflects confidence in Insmed’s pipeline, including Arikayce and TPIP, which are anticipated to contribute to a multi-billion dollar valuation. These recent developments underscore the investment community’s keen interest in Insmed’s innovative therapies and potential market opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.